Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials
PLOS One · 03.06.2026 · 21 (6) · e0349932
DOI: 10.1371/journal.pone.0349932 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS One, online erschienen am 03.06.2026. Verfasst von Ismaila Ajayi Yusuf und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Guthrie Robert Packer Hospital, Sayre, Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Hypertension, Cytochrome P-450 CYP11B2, Antihypertensive Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Aldosterone synthase inhibitors (ASIs) have emerged as a mechanistically targeted strategy for resistant and uncontrolled hypertension; however, no head-to-head trials exist, and comparative efficacy and safety remain uncertain. We compared their efficacy and safety using network and pairwise meta-analysis of randomized trials.
Methods
This systematic review and meta-analysis adhered to the PRISMA guidelines. PubMed/MEDLINE, Scopus, Embase, ClinicalTrials.gov, and Cochrane Library were searched from inception to January 14, 2026, for randomized trials evaluating ASIs versus placebo or standard care. A frequentist random-effects network meta-analysis assessed systolic (SBP) and diastolic blood pressure (DBP). Dichotomous safety outcomes were pooled using Hartung–Knapp random-effects models. Network consistency was evaluated using design-by-treatment interaction modeling. Prespecified subgroup analyses stratified outcomes by hypertension phenotype (resistant vs uncontrolled).
Results
Across 7 RCTs (n = 2,828), all ASIs significantly reduced SBP versus placebo: baxdrostat −8.63 mmHg (95% CI −10.84 to −6.42), lorundrostat −7.47 mmHg (95% CI −9.54 to −5.40), and LCI699/osilodrostat −5.63 mmHg (95% CI −9.15 to −2.12), with no significant indirect differences between agents. In resistant hypertension, lorundrostat (−9.00 mmHg; 95% CI −13.19 to −4.81) and baxdrostat (−8.77 mmHg; 95% CI −10.50 to −7.05) demonstrated pronounced reductions. In uncontrolled hypertension, LCI699/osilodrostat showed the largest point estimate (−10.55 mmHg; 95% CI −16.49 to −4.61), though this derives from a single early-phase trial and requires cautious interpretation. DBP reductions were significant for baxdrostat (−3.23 mmHg; 95% CI −4.73 to −1.73) and lorundrostat (−3.60 mmHg; 95% CI −5.43 to −1.77). Hypotension (RR 2.67), hyperkalemia (RR 7.94), and hyponatremia (RR 2.07) were significantly increased; serious adverse events, discontinuation, and network inconsistency were not detected.
Conclusions
ASIs provide clinically meaningful BP reduction across both hypertension phenotypes; however, short-term use is associated with hypotension and electrolyte disturbances, necessitating careful monitoring. Phenotype-specific efficacy and long-term safety require validation in outcome-driven trials. Systematic Review Registration: PROSPERO CRD420251266257
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Guthrie Robert Packer Hospital, Sayre, Pennsylvania, United States of America.
- Division of CardioNephrology, Cardiac Renal & Vascular Associates, Jackson, Mississippi, United States of America.
- Department of Medicine, University of Calabar, Calabar, Nigeria.
- Department of Epidemiology, Yale School of Public Health, New Haven, Connecticut, United States of America.
- Department of Medicine, Obafemi Awolowo University, Ile-Ife, Nigeria.
ORCID-Profile: Ismaila Ajayi Yusuf, Olurotimi J Badero, Alozie Ihesiulo, Micah Nnabuko Okwah, Emmanuella Asikong
Zitieren
APA
Yusuf, I. A., Badero, O. J., Ihesiulo, A., Okwah, M. N., Oshodin, A., & Asikong, E. (2026). Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials. PLOS One, 21(6), e0349932. https://doi.org/10.1371/journal.pone.0349932
Vancouver
Yusuf IA, Badero OJ, Ihesiulo A, Okwah MN, Oshodin A, Asikong E. Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials. PLOS One. 2026;21(6):e0349932. doi:10.1371/journal.pone.0349932
BibTeX
@article{Yusuf2026,
author = {Yusuf, Ismaila Ajayi and Badero, Olurotimi J and Ihesiulo, Alozie and Okwah, Micah Nnabuko and Oshodin, Abieyuwa and Asikong, Emmanuella},
title = {Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {6},
pages = {e0349932},
doi = {10.1371/journal.pone.0349932}
}
EUVIMED